RETRACTED: A DNA-based nanocarrier for efficient cancer therapy

Abbas, Muhammad; Zhang, Ya‐Liang; Yang, Yu‐Shun; Wu, Song-Yu; Hu, Yiqiao; Wang, Zhongchang; Zhu, Hai‐Liang

doi:10.1016/j.jpha.2020.03.005

Cited by 21 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DNA binding drugs, including CPT, can be loaded effectively on compact DNA nano-architecture, owing to their intrinsic DNA-binding ability [ 8 ]. DNA-based nanomaterials are becoming increasingly crucial as drug delivery carriers due to their nanoscale size precision and control that can be exerted over the shape of the material [ 9 , 10 ]. Some drugs have the intrinsic ability to bind with the DNA double helix, such as doxorubicin and cisplatin, which can be effectively loaded onto DNA-based carriers [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

The effective transfection of a low dose of negatively charged drug-loaded DNA-nanocarriers into cancer cells via scavenger receptors

Chengfei¹,

Akhtar²,

Ammara³

et al. 2021

Journal of Pharmaceutical Analysis

Self Cite

View full text Add to dashboard Cite

DNA-nanotechnology-based nano-architecture scaffolds based on circular strands were designed in the form of DNA-nanowires (DNA-NWs) as a polymer of DNA-triangles. Circularizing a scaffold strand (84-NT) was the critical step followed by annealing with various staple strands to make stiff DNA-triangles. Atomic force microcopy (AFM), native polyacrylamide gel electrophoresis (PAGE), UV-analysis, MTT-assay, flow cytometry, and confocal imaging were performed to assess the formulated DNA-NWs and cisplatin (CPT) loading. The AFM and confocal microscopy images revealed a uniform shape and size distribution of the DNA-NWs, with lengths ranging from 2 to 4 μm and diameters ranging from 150 to 300 nm. One sharp band at the top of the lane (500 bp level) with the loss of electrophoretic mobility during the PAGE (native) gel analysis revealed the successful fabrication of DNA-NWs. The loading efficiency of CPT ranged from 66.85% to 97.35%. MTT and flow cytometry results showed biocompatibility of the blank DNA-NWs even at 95% concentration compared with the CPT-loaded DNA-NWs. The CPT-loaded DNA-NWs exhibited enhanced apoptosis (22%) compared to the apoptosis (7%) induced by the blank DNA-NWs. The release of CPT from the DNA-NWs was sustained at < 75% for 6 h in the presence of serum, demonstrating suitability for systemic applications. The IC 50 of CPT@DNA-NWs was reduced to 12.8 nM CPT, as compared with the free CPT solution exhibiting an IC 50 of 51.2 nM. Confocal imaging revealed the targetability, surface binding, and slow internalization of the DNA-NWs in the scavenger-receptor-rich cancer cell line (HepG2) compared with the control cell line.

show abstract

Section: Introductionmentioning

confidence: 99%

The effective transfection of a low dose of negatively charged drug-loaded DNA-nanocarriers into cancer cells via scavenger receptors

Chengfei¹,

Akhtar²,

Ammara³

et al. 2021

Journal of Pharmaceutical Analysis

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this context, DNA nanostructures with suitable geometries and sizes make them ideal platforms for drug delivery applications, specifically in cancer therapy (Figure ). , Abbas et al designed DNA nanothreads loaded with cisplatin to provide controlled and prolonged release of the drug in cancer cells . Cytotoxicity assay showed enhanced apoptosis of cancer cells, achieved through endocytosis via scavenger receptors.…”

Section: Aptamer-functionalized Dna Nanodevices For Cancer Therapeuticsmentioning

confidence: 99%

“…54,55 Abbas et al designed DNA nanothreads loaded with cisplatin to provide controlled and prolonged release of the drug in cancer cells. 10 Cytotoxicity assay showed enhanced apoptosis of cancer cells, achieved through endocytosis via scavenger receptors. Chang et al designed 3D DNA icosahedra using a 5-point star motif for the efficient delivery of doxorubicin.…”

Section: Aptamer-functionalized Dna Nanodevicesmentioning

confidence: 99%

“…Different approaches are applied for the treatment of cancer including surgery, chemotherapy, hormone therapy, and radiation . However, all of these approaches deal with inherent drawbacks, such as poor targeting, passive bioactive components, and delivery into the cancerous as well as normal cells, resulting in low therapeutic effect and increased cytotoxicity. , These issues related to the present therapeutic approaches limit their widespread applications. To overcome the drawbacks of current technologies, early diagnosis methods are needed that can provide important information about changes in biomarkers and indicate disease progression, thereby aiding timely treatment .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Aptamer-Programmed DNA Nanodevices for Advanced, Targeted Cancer Theranostics

Walia

Chandrasekaran

Chakraborty³

et al. 2021

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

DNA has been demonstrated to be a versatile material for construction at the nanoscale. DNA nanodevices are highly programmable and allow functionalization with multiple entities such as imaging modalities (fluorophores), targeting entities (aptamers), drug conjugation (chemical linkers), and triggered release (photoresponsive molecules). These features enhance the use of DNA nanodevices in biological applications, catalyzing the rapid growth of this domain of research. In this review, we focus on recent progress in the development and use of aptamer-functionalized DNA nanodevices as theranostic agents, their characterization, applications as delivery platforms, and advantages. We provide a brief background on the development of aptamers and DNA nanodevices in biomedical applications, and we present specific applications of these entities in cancer diagnosis and therapeutics. We conclude with a perspective on the challenges and possible solutions for the clinical translation of aptamer-functionalized DNA nanodevices in the domain of cancer therapeutics.

show abstract

“…Even though all of the genetic alterations, especially anaplastic lymphoma kinase (ALK) fusion oncogene mutation and alteration in epidermal growth factor receptor (EGFR) in NSCLC, are well understood, certain limitations still need to be addressed (8)(9)(10). Recent research suggests that immunemediated disruption of carcinogens is more beneficial than the standard chemotherapeutic approach, so immunotherapy is under consideration for lung cancer treatment (11).…”

Section: Introductionmentioning

confidence: 99%

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment

Altaf

Jadoon²,

Muhammad³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer is one of the deadliest types of cancer responsible for thousands of cancer-related deaths. Its treatment has remained a challenge for researchers, but an increase in the knowledge of molecular pathways and biology of lung cancer has dramatically changed its management in recent decades. Immunotherapies and immunomodulation of lung cancer have previously failed for a long time but thanks to continuous research work and enthusiasm, now, this field is emerging as a novel effective therapy. Now, it is hope with potential benefits and promising results in the treatment of lung cancer. This review article focuses on immune checkpoints inhibitors: CTLA-4 inhibitors (ipilimumab and tremelimumab) and PDL-1 inhibitors (durvalumab and atezolizumab) that can be blocked to treat lung carcinoma. It is also focused on critically analyzing different studies and clinical trials to determine the potential benefits, risks, and adverse events associated with immunotherapeutic treatment.

show abstract

RETRACTED: A DNA-based nanocarrier for efficient cancer therapy

Cited by 21 publications

References 39 publications

The effective transfection of a low dose of negatively charged drug-loaded DNA-nanocarriers into cancer cells via scavenger receptors

The effective transfection of a low dose of negatively charged drug-loaded DNA-nanocarriers into cancer cells via scavenger receptors

Aptamer-Programmed DNA Nanodevices for Advanced, Targeted Cancer Theranostics

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment

Contact Info

Product

Resources

About